Biotech news, week of July 13, 2026

Monday, July 13, 2026

1. 0110:47 UTC

   Biotech venture funding hits $9.1B in first half of 2026

   2 outlets · first: BioPharma Dive Funding

   Reported by BioPharma Dive.

2. 0214:00 UTC

   NanoViricides gets ethics approval for Ebola trial in Congo

   1 outlet · first: tennesseedaily.com (Big News Network) Clinical trial

   Machine summary The reports also state that Ebola is spreading in two more provinces.

   1. The reports state that Ebola is spreading in two more provinces.

   Reported by tennesseedaily.com (Big News Network), hawaiitelegraph.com (Big News Network) and newjerseytelegraph.com (Big News Network).

   • NanoViricides, Inc.

3. 0319:00 UTC

   Coverage recordmcall.com: “Dozens at an Ebola treatment center in northeast Congo go on strike”

   1 outlet · first: mcall.com

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by mcall.com.

Tuesday, July 14, 2026

6 events. The full rundown for July 14, 2026. The most covered:

1. 09:45 UTC PBS review of MS treatments Ocrevus and Kesimpta reported 11
2. 16:20 UTC Cayman court orders Apple Tree partner to forfeit fund oversight 2
3. 18:00 UTC Reports: most new Ebola cases in eastern Congo from unknown chains 2

Wednesday, July 15, 2026

6 events. The full rundown for July 15, 2026. The most covered:

1. 11:45 UTC examiner.com.au: “Patient details exposed in medical centres cyberattack” 14
2. 17:00 UTC AACR report says funding changes disrupted cancer disparities research 10
3. 20:30 UTC States reach $18 million settlement with 23andMe 7

Thursday, July 16, 2026

1. 0417:00 UTC

   FDA approves once-daily oral PCSK9 inhibitor Lipfendra, Merck says

   8 outlets · first: iHeartRadio Fda approval

   Machine summary The U.S. Food and Drug Administration approved Lipfendra (enlicitide), a once-daily oral PCSK9 inhibitor, Merck announced Thursday. According to Merck's announcement, the tablet is approved for adults with hypercholesterolemia, including inherited forms, as an add-on to diet and other cholesterol-lowering therapies.

   Reported by iHeartRadio, mynbc5.com, wjcl.com, record-bee.com, sandiegouniontribune.com, wxii12.com, wyff4.com and wvtm13.com.

   • Food and Drug Administration
   • Lipfendra

   Full coverage: every report, when each was published, and who was named (8 outlets)

2. 0506:00 UTC

   Doctor alerts about symptoms of aggressive brain cancer

   5 outlets · first: nbcdfw.com Clinical trial

   Machine summary A doctor alerted about symptoms of an aggressive brain cancer, according to reports from NBC stations.

   1. A doctor alerted about symptoms of an aggressive brain cancer, according to NBC station reports.

   Reported by nbcdfw.com, nbcnewyork.com, nbcphiladelphia.com, nbcchicago.com and nbcconnecticut.com.

   • NBC

3. 0613:30 UTC

   Abbott raises 2026 profit forecast on diagnostics, device strength

   2 outlets · first: businesstimes Acquisition

   Machine summary The company said its cancer diagnostics business, including the recently acquired Exact Sciences' Cologuard and Oncotype DX, is helping offset declines in Covid-19 testing revenue.

   Reported by businesstimes and health.economictimes.indiatimes.com.

   • Exact Sciences
   • Cologuard
   • Oncotype DX

Friday, July 17, 2026

1. 0704:15 UTC

   CareDx +35% on Medicare Win; Atai +33% on $3.8B Lilly Deal

   2 outlets · first: Rttnews Pharma

   Machine summary CareDx rose 35% after Medicare finalized coverage for transplant rejection tests. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.

   1. AtaiBeckley shares surged over 33% following the announcement of its acquisition by Eli Lilly for $2.8 billion upfront plus up to $1.0 billion in CVRs tied to milestones for BPL-003 (Phase 3) and VLS-01 (Phase 2b) in treatment-resistant depression.
   2. Abbott Laboratories raised its full-year outlook after reporting better-than-expected Q2 2026 results, driving its shares higher.

   Reported by Rttnews and finanznachrichten.de.

   • Abbott Laboratories
   • CareDx
   • BPL-003
   • AtaiBeckley
   • Apollomics Inc.
   • VLS-01

2. 0811:15 UTC

   Medtronic and Apollo Hospitals announce partnership for advanced ICU in Hyderabad

   1 outlet · first: indiagazette.com (Big News Network) Pharma

   Machine summary Medtronic and Apollo Hospitals announced a strategic partnership to establish an advanced intensive care unit in Hyderabad, according to indiagazette.com.

   1. Medtronic and Apollo Hospitals announced a strategic partnership, according to indiagazette.com.
   2. The partnership is to establish a state-of-the-art advanced ICU in Hyderabad, according to indiagazette.com.

   Reported by indiagazette.com (Big News Network).

   • Medtronic
   • Advanced ICU ("ICU of the Future")

Saturday, July 18, 2026

1. 0915:00 UTC

   Health experts say gold mining worsens Zimbabwe malaria surge

   3 outlets · first: aol.co.uk

   Reported by aol.co.uk, zimbabwestar.com (Big News Network) and allafrica.com.

Sunday, July 19, 2026

1. 1023:30 UTC

   Samsung Biologics announces all-cash tender offer for PolyPeptide

   2 outlets · first: thailand-business-news.com Acquisition

   Machine summary Samsung Biologics announced an all-cash public tender offer for all fully diluted shares of PolyPeptide at CHF 44.31 each, manilatimes.net reported, valuing PolyPeptide’s equity at about CHF 1.46 billion.

   1. PolyPeptide's largest shareholder has given an irrevocable tender undertaking representing approximately 55.65% of outstanding shares (excluding treasury shares).

   Reported by manilatimes.net and thailand-business-news.com.

   • Samsung Biologics

What kind of news was it?

1. Pharma 11
2. Clinical trial 5
3. Fda approval 3
4. Funding 2
5. Acquisition 2
6. Gene therapy 1